Benzothiazepine and benzothiepine compounds

Details Benzothiazepine and benzothiepine compounds Benzothiazepine and benzothiepine compounds

2011-07-05

2011-07-05

Coleman, Brenda L (Department: 1624)

Drug, bio-affecting and body treating compositions

Designated organic active ingredient containing

Heterocyclic carbon compounds containing a hetero ring...

C514S217030, C514S228200, C514S232500, C514S233500, C514S249000, C514S252130, C514S297000, C514S305000, C514S307000, C514S314000, C514S316000, C514S324000, C514S333000, C514S337000, C514S414000, C514S422000, C514S431000, C540S467000, C540S596000, C544S058200, C544S062000, C544S079000, C544S145000, C544S351000, C544S376000, C546S102000, C546S134000, C546S137000, C546S139000, C546S170000, C546S175000, C546S187000, C546S202000, C546S256000, C546S279700, C548S504000, C548S525000, C548S950000, C549S009000

Reexamination Certificate

active

07973030

ABSTRACT:
A pharmaceutical useful as a therapeutic agent and a preventive agent for hyperlipemia, and a pharmaceutical useful as a therapeutic agent and a preventive agent for hepatic disorders associated with cholestasis, particularly, primary biliary cirrhosis and primary sclerosing cholangitis, and a pharmaceutical useful as a therapeutic agent and a preventive agent for obesity, fatty liver and steatohepatitis are provided. A benzothiazepine or benzothiepine compound represented by the following formula (1A) having a thioamide bond and a quaternary ammonium substitutent:

REFERENCES:
patent: 5723458 (1998-03-01), Brieaddy et al.
patent: 5817652 (1998-10-01), Brieaddy et al.
patent: 5910494 (1999-06-01), Brieaddy et al.
patent: 6277831 (2001-08-01), Frick et al.
patent: 7312208 (2007-12-01), Sasahara et al.
patent: 2005/0032776 (2005-02-01), Starke et al.
patent: 2 497 345 (2003-08-01), None
patent: 0 864 582 (1998-09-01), None
patent: 2002-519418 (2002-07-01), None
patent: 2002-536440 (2002-07-01), None
patent: 2002-533413 (2002-10-01), None
patent: 2002-541248 (2002-12-01), None
patent: WO 93/16055 (1993-08-01), None
patent: WO 97/33882 (1997-09-01), None
patent: WO 98/40375 (1998-09-01), None
patent: WO 99/32478 (1999-07-01), None
patent: WO 00/01687 (2000-01-01), None
patent: WO 00/47568 (2000-08-01), None
patent: 02/08211 (2002-01-01), None
patent: 02/50051 (2002-06-01), None
patent: WO 02/053548 (2002-07-01), None
patent: 2004/020421 (2004-03-01), None
Canadian Official Action—Application No. 2,557,576, Nov. 27, 2008.
U.S. Appl. No. 11/790,975, filed Apr. 30, 2007, Sasahara et al.
Telford D. E. et al., Inhibition of both the apical sodium-dependent bile acid transporter and HMG-CoA reductase markedly enhances the clearance of LDL apoB., J. Lipid. Rsd., 2003, vol. 44, No. 5, pp. 943 to 952.
Australian Patent Office issued an Australian Office Action dated Jun. 12, 2009, Application No. 2005217318.

Affiliated with

Also associated with

Rating

Benzothiazepine and benzothiepine compounds does not yet have a rating. At this time, there are no reviews or comments for this patent.

If you have personal experience with Benzothiazepine and benzothiepine compounds, we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and Benzothiazepine and benzothiepine compounds will most certainly appreciate the feedback.

Rate now

Comments { 0 }

Profile ID: LFUS-PAI-O-2680992